In this study, we discuss Z239-1907 affibody simultaneously targeting Axl and EGFR and the therapeutic efficacy of Z239-1907 in NPC-positive cells both in vitro and in vivo. This evidence concerns the gene EGFR and nasopharyngeal carcinoma.